Literature DB >> 7689442

Quinolones in Salmonella typhi infection.

H L DuPont1.   

Abstract

The quinolones possess a high degree of in vitro activity against enteric bacteria, including Salmonella. This observation, coupled with the limitations of current antityphoid agents, has resulted in the evaluation of quinolones in the therapy of S. typhi infection, including both enteric fever and chronic intestinal carriage. In open uncontrolled trials, norfloxacin, ciprofloxacin, ofloxacin and pefloxacin have been used successfully to treat more than 200 patients with culture-proven typhoid fever. In comparative clinical trials, ciprofloxacin, ofloxacin, pefloxacin or fleroxacin were equivalent or superior to standard antityphoid therapy. In separate studies, norfloxacin and ciprofloxacin were each effective in eliminating intestinal excretion of S. typhi in chronic carriers. Because of increasing resistance worldwide to conventional antityphoid drugs, and in view of the efficacy of the quinolones in the therapy of both typhoid fever and typhoid intestinal carriage, these drugs may become the treatment of choice for these important enteric infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689442     DOI: 10.2165/00003495-199300453-00020

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  In vitro activity of ofloxacin against 210 clinical isolates of typhoid salmonellae.

Authors:  A Hannan
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  Comparative study of ciprofloxacin versus co-trimoxazole in the treatment of Salmonella enteric fever.

Authors:  B M Limson; R T Littaua
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

3.  Norfloxacin in the treatment of infections caused by Salmonella typhi.

Authors:  M A Velmonte; C S Montalban
Journal:  Scand J Infect Dis Suppl       Date:  1988

4.  Ofloxacin in treatment of typhoid fever: a preliminary study.

Authors:  W L Lo
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

5.  Short-term ciprofloxacin therapy for typhoid fever.

Authors:  C Carbon; P Weber; M Levy; Y Boussougant; M Cerf
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

6.  Summary of an international workshop on typhoid fever.

Authors:  R Edelman; M M Levine
Journal:  Rev Infect Dis       Date:  1986 May-Jun

Review 7.  Current problems in antimicrobial therapy for bacterial enteric infection.

Authors:  H L DuPont; C D Ericsson; A Robinson; P C Johnson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults.

Authors:  M Hajji; N el Mdaghri; M Benbachir; K M el Filali; H Himmich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

9.  Use of norfloxacin to treat chronic typhoid carriers.

Authors:  E Gotuzzo; J G Guerra; L Benavente; J C Palomino; C Carrillo; J Lopera; F Delgado; D R Nalin; J Sabbaj
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

10.  Uptake of ciprofloxacin by macrophages.

Authors:  C S Easmon; J P Crane
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

View more
  9 in total

1.  Comparison of two regimens for ciprofloxacin treatment of enteric infections.

Authors:  C Agalar; S Usubütün; E Tütüncü; R Türkyilmaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

Review 2.  Quinolones in the treatment of typhoid fever.

Authors:  H E Akalin
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Detection and identification of ciprofloxacin-resistant Yersinia pestis by denaturing high-performance liquid chromatography.

Authors:  William Hurtle; Luther Lindler; Wei Fan; David Shoemaker; Erik Henchal; David Norwood
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

4.  Molecular analysis of and identification of antibiotic resistance genes in clinical isolates of Salmonella typhi from India.

Authors:  P M Shanahan; M V Jesudason; C J Thomson; S G Amyes
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 5.  The new quinolones in the treatment of diarrhoea and typhoid fever.

Authors:  A Waiz
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Fleroxacin vs Ciprofloxacin in the Management of Typhoid Fever: A Randomised, Open, Comparative Study in Nigerian Patients.

Authors:  C M Chukwuani; G C Onyemelukwe; P O Okonkwo; H A Coker; N D Ifudu
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 7.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

8.  Small Intestinal Infections.

Authors:  Saurabh Mehandru; Edmund J. Bini
Journal:  Curr Treat Options Gastroenterol       Date:  2001-04

9.  Biofilm Formation Protects Salmonella from the Antibiotic Ciprofloxacin In Vitro and In Vivo in the Mouse Model of chronic Carriage.

Authors:  Juan F González; Halley Alberts; Joel Lee; Lauren Doolittle; John S Gunn
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.